New dosing strategy aims to better protect Kids' organs from sickle cell damage
NCT ID NCT07177300
Summary
This study is testing a new, personalized way to start and adjust the dose of hydroxyurea, a standard medication for sickle cell disease, in young children. Researchers want to see if this tailored approach is better at protecting children's brains, hearts, kidneys, and spleens from long-term damage. The study will also closely monitor the long-term benefits and risks of taking hydroxyurea from a young age.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL ANEMIA (HBSS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.